首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 4期中西医结合肝胆胰疾病 => 肝纤维化及肝硬化 =>血清miRNA-122和紫藤..
血清miRNA-122和紫藤多花凝集素阳性Mac-2结合蛋白对慢性病毒性肝炎患者肝纤维化程度的预测价值
Value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein in predicting fibrosis degree in patients with chronic viral hepatitis
文章发布日期:2018年04月04日  来源:  作者:高敏,刘蓉,张庆  点击次数:365次  下载次数:80次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的探讨血清miRNA-122和紫藤多花凝集素阳性Mac-2结合蛋白(WFA+- M2BP)在慢性病毒性肝炎患者肝纤维化程度预测中的应用价值。方法选取2015年3月-2016年6月汉中市中心医院收治的行肝穿刺活组织检查的慢性乙型肝炎患者98例(CHB组)、慢性丙型肝炎患者104例(CHC组)和健康对照者56例(对照组)。实时荧光定量聚合酶链反应(real time-PCR)检测3组血清miRNA-122水平。HISCL M2BPGi检测系统检测血清WFA+- M2BP水平。计量资料2组间比较采用t检验,计数资料组间比较采用χ2检验。采用受试者工作特征曲线(ROC曲线)分析血清miRNA-122和WFA+- M2BP在肝炎患者肝纤维化程度中的预测价值,多因素联合分析采用logistic回归预测概率。结果CHB组和CHC组血清miRNA-122(t值分别为39.437、11.460,P值分别为<0.001和0.005)和WFA+-M2BP(t值分别为12.885、18.500,P值分别为0.004、0.002)显著高于对照组。CHB组肝纤维化分期S1~2患者血清miRNA-122显著高于S3~4患者(t=11.795,P=0.006)。CHB组和CHC组肝纤维化分期S1~2患者和肝脏炎症活动度分级G1~2患者血清WFA+-M2BP均显著低于对应组S3~4患者(t值分别为8.584、3565,P值分别为0.016、0.031)和G3~4患者(t值分别为5.568、3.354,P值分别为0.022、0.048)。ROC曲线分析发现miRNA-122和WFA+-M2BP预测CHB患者肝纤维化程度能效较好;WFA+-M2BP预测CHC患者肝纤维化程度能效较好(P<0.05),miRNA-122和WFA+-M2BP联合预测CHB和CHC肝纤维化程度能效好(AUC均>0.9,P值均为0.001)。结论血清miRNA-122和WFA+-M2BP联合可用于预测CHB和CHC患者肝纤维化程度。
【Abstract】:ObjectiveTo investigate the clinical value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) in predicting fibrosis degree in patients with chronic viral hepatitis. MethodsA total of 98 patients with chronic hepatitis B (CHB group) and 104 patients with chronic hepatitis C (CHC group), who were admitted to Hanzhong Municipal Hospital from March 2015 to June 2016 and underwent liver biopsy, were enrolled, and 56 healthy subjects were enrolled as control group. Quantitative real-time PCR was used to measure the serum level of miRNA-122 for all groups, and HISCL M2BPGi was used to measure the serum level of WFA+-M2BP. The t-test was used for comparison of continuous data between groups and the chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic (ROC) curve was used to analyze the value of serum miRNA-122 and WFA+-M2BP in predicting fibrosis degree in patients with hepatitis, and the logistic regression model was used to perform multivariate analysis and predict probability. ResultsCompared with the control group, the CHB group and the CHC group had significantly higher serum levels of miRNA-122 (t=39.437 and 11.460, P<0.001 and P=0.005) and WFA+-M2BP (t=12.885 and 18.500, P=0.004 and 0.002). In the CHB group, the patients with S1-2 fibrosis had a significantly higher serum level of miRNA-122 than those with S3-4 fibrosis (t=11.795, P=0.006). In the CHB group and the CHC group, the patients with S1-2 fibrosis and G1-2 liver inflammatory activity had a significantly lower serum level of WFA+-M2BP than those with S3-4 fibrosis (t=8.584 and 3.565, P=0.016 and 0031) and G3-4 liver inflammatory activity (t=5.568 and 3.354, P=0.022 and 0.048). The ROC curve analysis showed that miRNA-122 and WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHB patients, while WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHC patients (P<0.05); miRNA-122 combined with WFA+-M2BP had a high efficiency in predicting fibrosis degree in CHB and CHC patients (area under the ROC curve >0.9, all P=0.001). ConclusionSerum miRNA-122 combined with WFA+-M2BP can be used to predict fibrosis degree in both CHB and CHC patients.
【关键字】:肝炎, 乙型, 慢性; 肝炎, 丙型, 慢性; 肝硬化; 微RNAs; 植物凝集素类
【Key words】:hepatitis B, chronic; hepatitis C, chronic; liver cirrhosis; microRNAs; plant lectins
【引证本文】:GAO M, LIU R, ZHANG Q. Value of serum miRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein in predicting fibrosis degree in patients with chronic viral hepatitis[J]. J Clin Hepatol, 2018, 34(4): 764-769. (in Chinese)
高敏, 刘蓉, 张庆. 血清miRNA-122和紫藤多花凝集素阳性Mac-2结合蛋白对慢性病毒性肝炎患者肝纤维化程度的预测价值[J]. 临床肝胆病杂志, 2018, 34(4): 764-769.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号